This study introduces JS207, a novel BsAb targeting PD-1 and VEGFA, engineered to overcome resistance mechanisms in cancer therapy by concurrently inhibiting immunosuppressive and angiogenic pathways. This evidence concerns the gene PDCD1 and cancer.